Q2 2026 VC Trends : Advanced Drug Delivery Systems
Q2 2026 highlight: in the drug delivery sector, which spans a wide range of technologies and mechanisms, Q2 transactions favored delivery systems paired with a defined lead product and executable development path; platform breadth alone did not establish a valuation advantage.
This SRV review identifies valuation-relevant signals from selected recent transactions in the sector. It presents a public subset of the market analysis used in valuation work involving companies from Seed through Series C.
Sector reviewed : Advanced Drug Delivery Systems
Advanced drug delivery systems cover technologies whose principal value lies in transporting, targeting, releasing or localizing a therapeutic payload. This review includes transdermal and microneedle systems, nanoparticles and non-viral carriers, implants and depots, localized catheter or device delivery, CNS and blood–brain-barrier systems, and formulation technologies enabling alternative routes or controlled exposure.
The sector covers therapeutic areas globally, with emphasis on North America and Europe and financings from Seed through Series C.
For this review, conventional injectors and pumps are excluded ; payload-led biopharma, antibody–drug conjugates, radiopharmaceuticals and viral vectors are considered for context only unless the delivery layer is central.
From platform expansion to evidence-linked capital
Tracxn's drug-delivery dataset indicates a more selective environment: equity funding fell to US$431 million across 22 rounds in H1 2026 from US$634 million across 24 rounds in H1 2025. Its perimeter differs, so the figures are context, not SRV sector totals.
Earlier platform rounds were far larger. ReCode reported US$200 million of Series B funding in 2022; Aera launched in 2023 with US$193 million of combined Series A and B financing. Neither disclosed a private-company valuation. Later evidence separated platform promise from regulatory execution and strategic fit.
| Period | Key transaction evidence | Valuation signal |
|---|---|---|
| 2021–2023 expansion | ReCode-US$200M of Series B funding; Aera launched with US$193M of combined Series A and B financing. | Broad delivery platforms attracted preclinical capital. Round size is not valuation. |
| 2022–2025 divergence | Zosano entered Chapter 11 after FDA declined to review its microneedle-patch NDA resubmission. Halozyme later agreed to acquire Elektrofi for US$750M upfront plus up to US$150M in regulatory milestones. | Regulatory execution, partner fit and a scalable licensing model materially differentiated delivery-platform outcomes. |
| Q2 2026 | Anodyne closed a US$12.6M Series A; Advanced NanoTherapies closed more than US$31M in Series B financing; YolTech closed an approximately US$70M Series C. CeQur's US$100M Series E is later-stage context. | Financing varied with maturity; the amounts do not establish comparable valuations. |
Q2 2026: delivery systems with an executable product path
Anodyne Nanotech closed a US$12.6 million Series A to move its once-weekly GLP-1 microneedle patch toward Phase I and scale manufacturing. The same HeroPatch platform is intended to deliver peptides, antibodies and nucleic acids. The financing therefore paired one defined product with broader platform optionality.
Advanced NanoTherapies closed an oversubscribed Series B of more than US$31 million for SirPlux Duo, a nanoparticle-coated balloon that locally delivers paclitaxel and sirolimus. The investigational system has FDA Breakthrough Device designation and early clinical experience; proceeds support IDE work, manufacturing scale-up and pivotal preparation.
YolTech's approximately US$70 million Series C supplied adjacent evidence because its non-viral LNP system is combined with a late-clinical-stage gene-editing pipeline. Separately, T-CURX agreed to acquire Pantherna on undisclosed terms, bringing mRNA engineering and LNP delivery into one in-vivo CAR-T organization. Both cases combine delivery with proprietary therapeutic assets rather than valuing a standalone carrier.
Contrary evidence remained material. In June, FDA issued Camurus another Complete Response Letter for its monthly subcutaneous depot because of unresolved cGMP observations at a third-party manufacturer—not clinical efficacy or safety. The event illustrates how manufacturing readiness can delay value realization even after clinical development.
What changed — and what did not
Financing amounts are not valuations, and no selected private round disclosed a valuation. The grid therefore assesses which factors gained support in the curated evidence, not whether a sector-wide premium changed.
| Valuation factor | Q2 2026 assessment | Delta |
|---|---|---|
| Broad platform optionality alone | Present across several companies, but the selected evidence does not isolate its effect from lead products, stage or execution. | No change established |
| Lead product plus platform optionality | Anodyne and Advanced NanoTherapies linked financing to defined programs while preserving reuse across payloads or indications. | Strengthened |
| Clinical and regulatory maturity | Advanced NanoTherapies, YolTech and later-stage CeQur paired capital with clinical, regulatory or commercial progress. | Strengthened |
| Complex-payload or alternative-route enablement | Anodyne, YolTech and Pantherna show continued interest in delivery of large molecules or nucleic acids and in less burdensome administration. | Strengthened aelectively |
| Manufacturing and CMC readiness | Anodyne and Advanced NanoTherapies allocated proceeds to scale-up; Camurus' CRL exposed third-party manufacturing risk. | Strengthened |
| Strategic integration or licensing fit | T-CURX–Pantherna reinforced the integration signal established by Halozyme–Elektrofi, although the Q2 terms were undisclosed. | Strengthened selectively |
The quarter did not establish that delivery IP is interchangeable. It showed that the evidence surrounding the system—biodistribution or pharmacokinetics, product-specific efficacy, manufacturability, regulatory pathway and commercial route—remains material to financing interpretation.
Valuation perspective
The selected Q2 2026 evidence reinforced segmentation rather than a general valuation premium for drug delivery. For early-stage companies, transferability across payloads matters only alongside credible product selection, reproducible exposure and a feasible CMC plan. For clinical-stage companies, regulatory evidence, manufacturing readiness and a financeable route to commercialization become increasingly decisive.
SR Valuation Inc. (SRV) delivers startup valuation reports using BVM (the Backward Valuation Method): a benchmark valuation range (BVM Level 1) normalized for sector, stage, geography and macro economics applies; and company valuation (BVM Level 2) applying 4-dimension analytic to position the company vs. the benchmark.
Order a Benchmark Valuation Report (BVM Level 1)
Download this VC Trends Review (PDF) ↓
Methodology: This review considers selected financings, acquisitions and corporate or regulatory developments because of their relevance to startup valuation. It is not an exhaustive inventory of drug-delivery transactions, a sector investment report or investment advice. Sources were reviewed through July 19, 2026.
Sources: Tracxn, Drug Delivery — 2026 Market & Investments Trends; ReCode Therapeutics, Series B financing totaling US$200M (June 29, 2022); Aera Therapeutics, launch with US$193M in financing (February 16, 2023); Zosano Pharma, 2021 Form 10-K; Halozyme, Elektrofi acquisition agreement (October 1, 2025); Anodyne Nanotech, US$12.6M Series A (June 24, 2026); Advanced NanoTherapies, more than US$31M Series B (June 2, 2026); YolTech Therapeutics, approximately US$70M Series C (May 29, 2026); CeQur, US$100M Series E (June 9, 2026); HTGF, T-CURX acquisition of Pantherna Therapeutics (June 1, 2026); Camurus, regulatory update for Oclaiz (June 10, 2026). All sources were reviewed as available on July 19, 2026.
